Antibody-drug conjugate trial starts by region

3 regions, 2020 to 2025

349 Global, 2025

Antibody-drug conjugate trial starts by region: 3 regions, 2020 to 2025Antibody-drug conjugate trial starts by region: 3 regions, 2020 to 2025. 3 regions on one axis: Global, China, United States. 18 observations from 2020 to 2025, ranging from 25 to 638. Latest values: Global 349 (2025); China 177 (2025); United States 144 (2025). 0 200 400 600 800 2020 2021 2022 2023 2024 2025 Global China United States
Antibody-drug conjugate trial starts by region: 3 regions, 2020 to 2025Antibody-drug conjugate trial starts by region: 3 regions, 2020 to 2025. 3 regions on one axis: Global, China, United States. 18 observations from 2020 to 2025, ranging from 25 to 638. Latest values: Global 349 (2025); China 177 (2025); United States 144 (2025). 0 200 400 600 800 2020 2021 2022 2023 2024 2025 Global China United States
Antibody-drug conjugate trial starts by region: 3 regions, 2020 to 2025Antibody-drug conjugate trial starts by region: 3 regions, 2020 to 2025. 3 regions on one axis: Global, China, United States. 18 observations from 2020 to 2025, ranging from 25 to 638. Latest values: Global 349 (2025); China 177 (2025); United States 144 (2025). 0 200 400 600 800 2020 2021 2022 2023 2024 2025 Global China United States
View the underlying data
Antibody-drug conjugate trial starts by region: 3 regions, 2020 to 2025
Region Period Type Value
Global 2025 Actual 349
Global 2024 Actual 282
Global 2023 Actual 233
Global 2022 Actual 176
Global 2021 Actual 145
Global 2020 Actual 101
China 2025 Actual 177
China 2024 Actual 150
China 1 Jan 2023 to 27 Sep 2026 Actual 638
China 2022 Actual 69
China 2021 Actual 40
China 2020 Actual 25
United States 2025 Actual 144
United States 2024 Actual 105
United States 2023 Actual 94
United States 2022 Actual 96
United States 2021 Actual 94
United States 2020 Actual 73
Chart: StatOrigin · Source: ClinicalTrials.gov · statorigin.org CC BY 4.0